Daebongls.Co.Ltd (078140) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Daebongls.Co.Ltd KRW 13,809, price KRW 7,380, upside +87.1%, quality 44 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Daebongls.Co.Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 6,803 KRW – 23,561 KRW · fair‑value band 9,973 KRW – 17,261 KRW · the 7,380 KRW price screens below the 13,809 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Daebongls.Co.Ltd in your weekly email
Every Wednesday you see whether Daebongls.Co.Ltd is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Daebongls.Co.,Ltd. engages in the research, development, and production of cosmetics, pharmaceutical raw materials, food and feed products in South Korea and internationally.
Show more
Daebongls.Co.,Ltd. engages in the research, development, and production of cosmetics, pharmaceutical raw materials, food and feed products in South Korea and internationally. The company's Cosmetic Ingredients division offers special cosmetic ingredients comprising fresh green tea, black ginseng water, jeju hatban extract, wormwood extract, jeju camellia oil, jeju dang oil extract, jeju basalt powder, jeju active complex, and ginseng flower extract; and natural and synthesis cosmetics like moisturizing, skin protection, whitening, anti- aging, skin care, and hair care products. The company's Pharmaceutical Raw Material division develops the API of respiratory, hypertension, digestive-system treatments, and medicines and supply excipients to domestic companies as an agent for global companies. The company's Food & Feed division manufactures and distributes functional additives, protein products, amino acids, and vitamins. Daebongls.Co.,Ltd. was founded in 1986 and is headquartered in Incheon, South Korea.
Stock analysis
Daebongls.Co.Ltd (078140) currently trades at 7,380 KRW, while our model-based Fair Value estimate is 13,809 KRW, implying the stock looks roughly 46.6% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 14,248 KRW per share, and 7 of the 12 models we run sit above the 7,380 KRW price.
Bear case: the Multiples group reads lowest at 5,327 KRW, and 5 of the 12 models stay below the price. Evidence for this calculation is low.
Scenario range: 9,973 KRW (bear) to 17,261 KRW (bull), the price of 7,380 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Daebongls.Co.Ltd reported revenue of 102B KRW in FY2025 versus 83.0B KRW in FY2021, a compound +5.3%/yr. Reported net income was 10.1B KRW in FY2025, compounding +10.3%/yr from FY2021.
Key figures
Market cap 80.8B KRW (≈ $59.4M) · P/S ratio 0.94 · Dividend yield 0.4% · Net margin 9.9% · Return on equity 713% · Return on assets (EBIT) 3.8% · Operating margin 10.1% · Revenue (TTM) 92.0B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 49 out of 100 (low confidence).
What moves the price
The share trades about 45% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −41% fair-value upside, at 87%, 078140 screens cheaper than that median.
Fair Value models
Bear 9,973 KRWFair Value 13,809 KRWBull 17,261 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+8.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.0%
Start year 2020 (pandemic). Over 10 years: +5.7% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.3%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−1.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year−1.9%
Dividend (yield on the price)0.4%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.12% vs 2%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.11% → 7%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceuticals · 55 stocks
Beats the industry median on 5/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score44 · Below median
Fair Value upside+87% · Top 25%
Profitability
Return on assets3% · Above median
Net margin (TTM)5% · Above median
Operating margin (TTM)10% · Above median
Growth and dividend
Revenue growth10% · Below median
Dividend yield (TTM)0.4% · Below median
Balance sheet
Debt / equity0.47× · Highest 25%
Valuation Multiplesvs Pharmaceuticals median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Daebongls.Co.Ltd Fair Value". https://www.fairvalue-calculator.com/stock/078140
Frequently asked questions
Is Daebongls.Co.Ltd (078140) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 13,809 KRW versus a price of 7,380 KRW, about +87% upside (undervalued).
What is the fair value of 078140?
Our model-based fair value for Daebongls.Co.Ltd is 13,809 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 7,380 KRW.
What is the quality score of 078140?
Daebongls.Co.Ltd has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Daebongls.Co.Ltd (078140)?
Our model-based price target is the fair value of 13,809 KRW (as of Sep 24, 2026) from 12 valuation models. Cautious scenario 9,973 KRW, optimistic scenario 17,261 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Daebongls.Co.Ltd stock forecast for 2026?
Our models put fair value at 13,809 KRW, about +87% upside versus a price of 7,380 KRW (undervalued). Cautious scenario 9,973 KRW, optimistic scenario 17,261 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Daebongls.Co.Ltd (078140)?
Daebongls.Co.Ltd reported trailing-twelve-month revenue of about 92.0B KRW (latest available figure, as of Sep 24, 2026).
Does Daebongls.Co.Ltd pay a dividend?
Daebongls.Co.Ltd currently shows a dividend yield of about 0.42% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Daebongls.Co.Ltd (078140)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Daebongls.Co.Ltd it is 13,809 KRW per share (as of Sep 24, 2026), against a price of 7,380 KRW. It is the blended result of 12 valuation models (cash flow, earnings, asset, dividend).
Is Daebongls.Co.Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 078140 trades below its calculated fair value: price 7,380 KRW, fair value 13,809 KRW, a gap of about +87% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 078140?
No. The price is what the market pays today (7,380 KRW); the fair value is what the company's own numbers justify (13,809 KRW). For Daebongls.Co.Ltd the two are 6,429 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Daebongls.Co.Ltd worth?
The market values Daebongls.Co.Ltd at about 80.8B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 7,380 KRW; our models calculate a fair value of 13,809 KRW per share.
What do the bullish and bearish scenarios say about 078140?
Our models span a range for Daebongls.Co.Ltd: cautious scenario 9,973 KRW, base 13,809 KRW, optimistic 17,261 KRW per share (as of Sep 24, 2026, price 7,380 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Daebongls.Co.Ltd (078140)?
Balance-sheet figures for Daebongls.Co.Ltd (as of Sep 24, 2026): debt of 0.47 per unit of equity. They feed the Quality Score of 44/100, which measures business quality independently of the share price.
How far is 078140 from its 52-week high?
Daebongls.Co.Ltd trades at 7,380 KRW, about 45% below its 52-week high of 13,493 KRW and 5% above the low of 7,020 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 13,809 KRW is for.
Which stocks are comparable to Daebongls.Co.Ltd?
From the same area (Healthcare) we also value Caregen Co, ST Pharm Co, Oscotec Inc, DongKook Pharmaceutical Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Daebongls.Co.Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 7,380 KRW, calculated fair value 13,809 KRW (+87%), Quality Score 44/100, from 12 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 078140 calculated?
We run Daebongls.Co.Ltd through 12 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 13,809 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Daebongls.Co.Ltd currently trades 87 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Daebongls.Co.Ltd (078140)?
The closing price on Sep 23, 2026 was 7,380 KRW. Our model-based fair value is 13,809 KRW, about +87% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Daebongls.Co.Ltd right now?
The large discount to fair value meets weak quality (44/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (9,973 KRW). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Daebongls.Co.Ltd
How large is the market capitalisation of Daebongls.Co.Ltd (078140)?
The market capitalisation of Daebongls.Co.Ltd is 80.8B KRW (≈ $59.4M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Daebongls.Co.Ltd (078140)?
The price-to-sales ratio of Daebongls.Co.Ltd is 0.94 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Daebongls.Co.Ltd (078140)?
The dividend yield of Daebongls.Co.Ltd is 0.4%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Daebongls.Co.Ltd (078140)?
The net margin of Daebongls.Co.Ltd is 9.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Daebongls.Co.Ltd (078140)?
The return on equity (ROE) of Daebongls.Co.Ltd is 713% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Daebongls.Co.Ltd (078140)?
On an EBIT basis the return on assets of Daebongls.Co.Ltd is 3.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Daebongls.Co.Ltd (078140)?
The operating margin of Daebongls.Co.Ltd is 10.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Daebongls.Co.Ltd (078140)?
Revenue at Daebongls.Co.Ltd is growing +10.2% versus a year earlier (3y avg +3.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Daebongls.Co.Ltd (078140)?
Earnings per share at Daebongls.Co.Ltd are growing +17.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Daebongls.Co.Ltd (078140) generate?
The free cash flow of Daebongls.Co.Ltd is −30.7B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Daebongls.Co.Ltd (078140) carry?
The net debt of Daebongls.Co.Ltd is 63.3B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Daebongls.Co.Ltd in the live analysis
One click puts Daebongls.Co.Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
